According to reports from The Financial Express, two prominent healthcare stocks have seen significant promoter stake reductions that have not deterred major investors. Beta Drugs Ltd experienced a 7 percentage point decline in promoter holding from 66.73% in September 2025 to 59.10% by June 2026, while Suven Life Sciences saw a 5 percentage point drop from 70.08% to 65.47% in July 2026 alone. Despite these substantial declines, both stocks continue to attract institutional interest, with Beta Drugs maintaining its position among India's top 10 oncology companies and Suven Life Sciences focusing on clinical-stage drug development.
As reported by The Financial Express, Beta Drugs Ltd has demonstrated consistent financial performance with sales growing at 27% CAGR from ₹116 crore in FY21 to ₹385 crore in FY26. The company's EBITDA expanded at 25% CAGR over the same period, maintaining steady operating margins of 19-23%. The June 2026 quarter showed particularly strong momentum with sales rising 25% year-on-year to ₹126 crore and net profit climbing 35% to ₹16 crore, marking the company's strongest quarter on record. Ashish Kacholia currently holds close to 11% stake worth ₹290 crore, maintaining his position since March 2019 when his holding was 1.2%.
According to The Financial Express, Suven Life Sciences operates as a clinical-stage drug developer with sales of ₹7 crore in FY26, reflecting the company's focus on research and development. The company has incurred losses of ₹276 crore in FY26 against minimal revenue, with EBITDA losses of ₹284 crore as it invests heavily in clinical trials. The July 2026 promoter stake reduction was primarily due to warrant conversions totaling ₹248.84 crore, which created fresh shares and diluted existing holdings. Sunil Singhania's Abakkus Diversified Alpha Fund holds a 1% stake worth approximately ₹87 crore in the company.
As reported by The Financial Express, Beta Drugs shares have experienced significant appreciation, rising from around ₹340 in August 2021 to ₹2,347 as of August 2026, representing a 590% increase over five years. The stock currently trades at a PE ratio of 57x, substantially above the industry median of 33x. Suven Life Sciences has seen its share price increase from approximately ₹80 in August 2021 to ₹310 in August 2026, a 288% jump over five years. The company trades at around 14 times its book value with negative ROCE of minus 80%, reflecting its pre-revenue clinical development phase.
According to The Financial Express, both stocks continue to attract institutional interest despite promoter stake reductions, with Beta Drugs maintaining its position among India's top 10 oncology companies and Suven Life Sciences focusing on clinical-stage drug development. The analysis suggests that retail investors often misinterpret promoter stake declines, failing to understand corporate actions such as preferential issues and warrant conversions that create new shares without actual sales. Both stocks have shown strong institutional participation, with Beta Drugs seeing domestic institutional holdings increase from 0.29% to 6.23% and Suven Life Sciences attracting multiple institutional funds including Quant Small Cap Fund and 3P India Equity Fund 1.
